Epidemiology of prostate cancer in Asian countries

Kimura, Takahiro; Egawa, Shin

doi:10.1111/iju.13593

Cited by 288 publications

(239 citation statements)

References 80 publications

Supporting

Mentioning

229

Contrasting

Unclassified

Order By: Relevance

“…In Asia, the incidence is increasing. The reasons for this increase include the implementation of PSA testing, development of cancer registry, risky behaviours associated with economic growth and the influence of environmental risk factors [5].…”

Section: Introductionmentioning

confidence: 99%

Presentation, Characteristics and Co-morbidities of Men with Prostate Cancer in Nigeria

Ofoha

Magnus

2019

JAMMR

View full text Add to dashboard Cite

Aims:To determine the presentation, characteristics and associated co-morbidities in Nigerian men with prostate cancer. Methodology: Men with histologically confirmed prostate cancer were analyzed. The age of the men, PSA pattern, histologic type, Gleason score, stage of the disease, associated co-morbidities and treatment received by the men were recorded. The effect of co-morbidities on disease aggressiveness using Gleason score and PSA as determinants was determined using Pearson correlation. SPSS version 23 was used in analyzing the data. P-value of < 0.05 was considered significant. Results: Eighty-one patients with prostate cancer from 2010 to 2018 were involved in the study. The mean age was 67.58±9.42 years with a range of 42 to 96years. Men with PSA >100 ng/ml had the highest frequency (34.60%). The mean Gleason Score was 6.28±2.13. Gleason score 7-8 had the highest frequency (35.8%). Seventy-nine patients (97.5%) had adenocarcinoma. Eighty- Ofoha and Magnus; JAMMR, 31(5): 1-7, 2019; Article no.JAMMR.52918 2 one percent of the men had advanced Pca, 58% being metastatic disease. 48.1% had comorbidities, 39.5% had hypertension, while 8.6% had both hypertension and diabetes. Comorbidities showed no correlation with PSA level (r=0.346), (p-value 0.375) and Gleason score (r=0.194), (p-value 0.639). Seventy-nine percent of the men had androgen deprivation therapy. Conclusion: Most of the men presented with advanced disease, with all indices pointing towards lethal disease. The commonest co-morbidity was hypertension and co-morbidities had no relationship with the aggressiveness of prostate cancer. To ensure early presentation and prevent lethal forms of Pca, health education, screening, counselling for men in the high-risk group is paramount. Original Research Article

show abstract

Section: Introductionmentioning

confidence: 99%

Presentation, Characteristics and Co-morbidities of Men with Prostate Cancer in Nigeria

Ofoha

Magnus

2019

JAMMR

View full text Add to dashboard Cite

show abstract

“…In 2018, the National Cancer Center Japan estimated that the number of newly diagnosed prostate cancer patients was in the fourth degree (78 400 patients) among all men with cancer. In Asia, the incidence and mortality trends of prostate cancer differ from Western countries, with the incidence and mortality of prostate cancer on the increase, except for Australia, New Zealand, Japan and Korea. The reason for this trend is multifactorial and includes, for example, changes in lifestyle as a result of more Westernized diets, immature early detection systems and the accuracy of national cancer registration systems.…”

Section: Introductionmentioning

confidence: 98%

Quality of life in active surveillance for early prostate cancer

Kato

Sugimoto

2020

Int J of Urology

View full text Add to dashboard Cite

Recently, the prevalence of the prostate‐specific antigen screening test for early‐stage prostate cancer has increased, but this has also resulted in an increase in insignificant cancers. The treatment outcome of early‐stage prostate cancer is excellent, but such a radical treatment also leaves the patient with undesired adverse consequences. To resolve such problems, attention should be paid to active surveillance as a modern treatment option. This study aimed to systematically review the literature about quality of life in prostate cancer patients undergoing active surveillance. Evidence was acquired from PubMed databases in March 2019 using quality of life, prostate cancer, well‐being, anxiety, depression, stress, outcomes, active surveillance, radiation therapy and radical prostatectomy as keywords. Five clinical active surveillance studies measured health‐related quality of life and related psychological factors, and seven compared active surveillance with other treatments (radical therapy and hormone therapy). Active surveillance was superior to radical therapy for urinary and sexual function. Furthermore, most patients who opted for active surveillance showed lower anxiety and fear of progression, whereas health‐related quality of life was maintained. Although active surveillance has the advantage of being non‐invasive, its diagnosis and follow‐up protocols are unreliable. Because such uncertainty can affect patients’ quality of life, utilization of imaging modalities, such as magnetic resonance imaging, and the development of new biomarkers are required.

show abstract

“…The incidence and mortality of cancer has been of great public concern worldwide (Chen, Sun, et al, ; Dal Maso et al, ; Kimura & Egawa, ). One of the important reasons for the rapid increase of mortality and morbidity is the lack of sensitive biomarkers that can be used for early detection and diagnosis among various types of cancer.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic performance of circular RNAs in human cancers: A systematic review and meta‐analysis

et al. 2019

Molec Gen & Gen Med

View full text Add to dashboard Cite

Background Recently, accumulating evidence have revealed that circular RNA (circRNA) was deregulated in multiple types of cancer, suggesting that circRNA might serve as a novel candidate biomarker of cancer diagnosis. However, inconsistent results have become an obstacle in applying circRNAs to clinical practice. The aim of this study is to evaluate diagnostic value of circRNAs among cancers. Methods A literature search was systematically performed among PubMed, Sciencedirect, Cochrane Library, Web of Science, Wanfang, and Chinese National Knowledge Infrastructure databases up to February 15, 2019. The pooled sensitivity (SEN), specificity (SPE), positive likelihood ratios, negative likelihood ratios, diagnostic odds ratio, and area under the SROC curve (AUC) were applied to evaluate diagnostic performance of circRNAs. Results In total, the study included 64 studies with single circRNA and 13 studies with combined circRNAs. Overall, the study presented that a single circRNA had moderate diagnostic value, with a SEN of 0.75, a SPE of 0.76, and an AUC of 0.82. The plasma circRNAs had higher diagnostic accuracy than tissue (AUC: 0.87, 95% confidence interval [CI]: 0.83–0.89 for plasma/serum subgroup; AUC: 0.79, 95% CI: 0.75–0.82 for tissue subgroup). Furthermore, the combined circRNAs had good diagnostic efficacy for GC, with a SEN of 0.89, a SPE of 0.94, and an AUC of 0.97, respectively. Conclusion This study confirmed that circRNAs may be candidate biomarkers for cancer diagnosis. In particular, diagnosis of combined circRNAs will be a new alternative applied to clinical research and practice for cancer.

show abstract

Epidemiology of prostate cancer in Asian countries

Cited by 288 publications

References 80 publications

Presentation, Characteristics and Co-morbidities of Men with Prostate Cancer in Nigeria

Presentation, Characteristics and Co-morbidities of Men with Prostate Cancer in Nigeria

Quality of life in active surveillance for early prostate cancer

Diagnostic performance of circular RNAs in human cancers: A systematic review and meta‐analysis

Contact Info

Product

Resources

About